AHR and myeloid sarcoma: Because AhR ligands are known immuno-modulators in multiple sclerosis (MS)8–10, in particular by diet administration11, here we have investigated the impact of systemic administration of 3-IAld in a mouse model of MS, thus proposing a protective role for AhR activation driven by the microbiome.